Janssen Pharmaceutical Cos.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janssen Pharmaceutical Cos.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
The EU’s backing for a new prophylactic vaginal ring containing dapirivine is being seen as a welcome addition to efforts to tackle the spread of HIV in lower resourced countries, particularly in sub-Saharan Africa. But there are still some hurdles to overcome before it can be made available to those who are in most urgent need.